Roche news

The AI-based tool aids early CKD risk assessment, integrating with existing systems to enhance patient care and reduce healthcare costs. Available in Europe, UK; US, Middle East, Asia to follow.

Dr. Claudia Süssmuth Dyckerhoff will not seek re-election to Roche's Board in 2026, opting for a board role at another healthcare company. She has been a board member since 2016.

Tender offer expires Oct 29, 2025. Includes CVR up to $6.00. Requires majority share tender, no financing condition. Second-step merger follows at same terms. Completion expected Q4 2025.

The new test improves heart attack diagnosis speed and accuracy, aiding emergency care efficiency and patient outcomes, validated by a global study of over 13,000 participants.

OCREVUS shows reduced disability progression in MS patients; fenebrutinib demonstrates near-complete disease activity suppression over two years.

Phase III trial shows giredestrant plus everolimus improves progression-free survival in ER-positive breast cancer, with no new safety concerns.

Lunsumio SC offers faster administration and high response rates for relapsed follicular lymphoma, with low cytokine release syndrome risk, pending EU approval.

Roche enhances its CVRM portfolio with 89bio's pegozafermin, targeting MASH. The deal is valued up to $3.5 billion, with potential milestone payments. Completion expected Q4 2025.

Contivue with Susvimo offers continuous nAMD treatment, showing stable long-term vision outcomes with up to two refills yearly, backed by seven-year LADDER study data.

Investing in new R&D and office buildings, infrastructure upgrades, and historic renovations, the plan aims to consolidate operations, enhance sustainability, and improve work environments.